---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-053953"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:51:31.901402+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MindMed doses first patient in Phase 3 Emerge study of MM120 ODT for MDD

## Summary
- First patient dosed in Phase 3 Emerge study evaluating MM120 ODT 100 µg vs placebo in major depressive disorder.
- Primary endpoint: change from baseline in MADRS score at Week 6; ~140 participants expected in U.S.
- Topline data from the 12-week double-blind period anticipated in second half of 2026.
- Emerge is the third Phase 3 study of MM120 ODT; Voyage and Panorama studies in GAD are already underway.
- Phase 2b GAD study showed clinically and statistically significant MADRS improvements after single 100 µg dose.

## SEC filing metadata
- accession: 0000950170-25-053953
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017025053953/0000950170-25-053953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017025053953/mnmd-20250415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-053953
- JSON: https://secwatch.observer/filing/0000950170-25-053953.json
- Plain text: https://secwatch.observer/filing/0000950170-25-053953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.